ZNF174

Summary

ZNF174 (zinc finger protein 174, HGNC:12963) is a protein-coding gene on chromosome 16p13.3, encoding Zinc finger protein 174 (Q15697). Transcriptional repressor.

This gene encodes a protein with three Cys2-His2-type zinc fingers in the carboxy-terminus, a putative nuclear localization signal, and an amino-terminus SCAN box which forms homodimers. This protein is believed to function as a transcriptional repressor. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 7727 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 69 total
• MANE Select transcript: NM_003450

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12963
Approved symbol	ZNF174
Name	zinc finger protein 174
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	ZSCAN8
Ensembl gene	ENSG00000103343
Ensembl biotype	protein_coding
OMIM	603900
Entrez	7727

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000268655, ENST00000344823, ENST00000571936, ENST00000572544, ENST00000575752, ENST00000959344

RefSeq mRNA: 5 — MANE Select: NM_003450 NM_001032292, NM_001347868, NM_001347869, NM_001347870, NM_003450

CCDS: CCDS10504, CCDS32380, CCDS86501

Canonical transcript exons

ENST00000268655 — 3 exons

Exon	Start	End
ENSE00000666899	3408321	3409364
ENSE00001838202	3401215	3402406
ENSE00003488193	3404426	3404648

Expression profiles

Bgee: expression breadth ubiquitous, 206 present calls, max score 90.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.1362 / max 54.2742, expressed in 1756 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
152423	10.1362	1756

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	90.30	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.85	gold quality
apex of heart	UBERON:0002098	82.66	gold quality
cortical plate	UBERON:0005343	80.78	gold quality
gastrocnemius	UBERON:0001388	80.59	gold quality
muscle of leg	UBERON:0001383	80.25	gold quality
muscle layer of sigmoid colon	UBERON:0035805	80.23	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.14	gold quality
popliteal artery	UBERON:0002250	80.07	gold quality
tibial artery	UBERON:0007610	80.05	gold quality
right uterine tube	UBERON:0001302	79.98	gold quality
lower esophagus muscularis layer	UBERON:0035833	79.91	gold quality
lower esophagus	UBERON:0013473	79.89	gold quality
right coronary artery	UBERON:0001625	79.68	gold quality
heart left ventricle	UBERON:0002084	79.43	gold quality
aorta	UBERON:0000947	79.31	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	79.21	gold quality
granulocyte	CL:0000094	79.03	gold quality
islet of Langerhans	UBERON:0000006	79.02	gold quality
descending thoracic aorta	UBERON:0002345	78.96	gold quality
cardiac ventricle	UBERON:0002082	78.89	gold quality
hindlimb stylopod muscle	UBERON:0004252	78.89	gold quality
thoracic aorta	UBERON:0001515	78.84	gold quality
body of uterus	UBERON:0009853	78.78	gold quality
cervix squamous epithelium	UBERON:0006922	78.74	silver quality
ascending aorta	UBERON:0001496	78.72	gold quality
left coronary artery	UBERON:0001626	78.65	gold quality
right atrium auricular region	UBERON:0006631	78.60	gold quality
ventricular zone	UBERON:0003053	78.45	gold quality
right adrenal gland cortex	UBERON:0035827	78.40	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.10

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
PDGFB
TGFB1	Repression

miRNA regulators (miRDB)

28 targeting ZNF174, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-5700	99.64	69.88	2280
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-8070	99.07	69.30	1303
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-4744	99.01	69.91	1581
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-502-5P	98.77	66.51	906
HSA-MIR-188-5P	97.89	67.01	756
HSA-MIR-3620-3P	97.78	64.88	772
HSA-MIR-6866-3P	97.38	66.94	748
HSA-MIR-4288	97.11	67.23	1636
HSA-MIR-339-5P	96.73	66.01	820
HSA-MIR-6847-3P	96.50	67.30	582
HSA-MIR-4774-5P	95.92	68.27	827
HSA-MIR-1231	95.10	65.63	663
HSA-MIR-877-5P	94.62	66.30	710

Literature-anchored findings (GeneRIF, showing 1)

• Both size exclusion chromatography and equilibrium sedimentation analysis demonstrate that the ZNF174 SCAN domain forms a homodimer (PMID:11741982)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	plagx	ENSDARG00000036855
danio_rerio	ovol1a	ENSDARG00000076472
danio_rerio	plagl2	ENSDARG00000076657
danio_rerio	ovol1b	ENSDARG00000078256
mus_musculus	Zfp174	ENSMUSG00000054939
rattus_norvegicus	Zfp174	ENSRNOG00000007655
drosophila_melanogaster	hb	FBGN0001180
drosophila_melanogaster	CG12391	FBGN0033581
caenorhabditis_elegans		WBGENE00001824
caenorhabditis_elegans		WBGENE00003033
caenorhabditis_elegans		WBGENE00012385

Paralogs (29): ZNF446 (ENSG00000083838), REST (ENSG00000084093), OVOL3 (ENSG00000105261), PLAGL1 (ENSG00000118495), ZSCAN18 (ENSG00000121413), ZNF576 (ENSG00000124444), OVOL2 (ENSG00000125850), PLAGL2 (ENSG00000126003), ZSCAN5A (ENSG00000131848), ZSCAN29 (ENSG00000140265), ZSCAN32 (ENSG00000140987), ZSCAN1 (ENSG00000152467), ZNF18 (ENSG00000154957), ZKSCAN2 (ENSG00000155592), ZNF496 (ENSG00000162714), ZNF202 (ENSG00000166261), ZNF641 (ENSG00000167528), ZNF444 (ENSG00000167685), SCAND1 (ENSG00000171222), ZNF274 (ENSG00000171606), ZNF131 (ENSG00000172262), OVOL1 (ENSG00000172818), ZNF518A (ENSG00000177853), ZNF518B (ENSG00000178163), PLAG1 (ENSG00000181690), ZSCAN5B (ENSG00000197213), ZNF770 (ENSG00000198146), PEG3 (ENSG00000198300), ZSCAN5C (ENSG00000204532)

Protein

Protein identifiers

Zinc finger protein 174 — Q15697 (reviewed: Q15697)

Alternative names: AW-1, Zinc finger and SCAN domain-containing protein 8

All UniProt accessions (2): Q15697, I3L2H2

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional repressor.

Subunit / interactions. Homodimer.

Subcellular location. Nucleus.

Tissue specificity. Expressed in a variety of organs, but most strongly in adult testis and ovary followed by small intestine, colon, prostate, thymus, spleen, pancreas, skeletal muscle, heart, brain and kidney. Also expressed in umbilical vein endothelial cells, foreskin fibroblast and Hep-G2 cells.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15697-1	1	yes
Q15697-2	2

RefSeq proteins (5): NP_001027463, NP_001334797, NP_001334798, NP_001334799, NP_003441* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003309	SCAN_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR038269	SCAN_sf	Homologous_superfamily
IPR050916	SCAN-C2H2_zinc_finger	Family

Pfam: PF00096, PF02023

UniProt features (20 total): helix 5, cross-link 4, zinc finger region 3, splice variant 2, region of interest 2, chain 1, domain 1, strand 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1Y7Q	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15697-F1	60.62	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 230, 271, 26, 204

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 62 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, CCCNNNNNNAAGWT_UNKNOWN, AACTTT_UNKNOWN, DANG_BOUND_BY_MYC, GOCC_NUCLEAR_BODY, GOCC_NUCLEOLUS, BENPORATH_MYC_MAX_TARGETS, KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, GOMF_PROTEIN_HOMODIMERIZATION_ACTIVITY, LIU_NASOPHARYNGEAL_CARCINOMA, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN, FIGUEROA_AML_METHYLATION_CLUSTER_6_UP, FIGUEROA_AML_METHYLATION_CLUSTER_7_UP

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (11): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), protein homodimerization activity (GO:0042803), sequence-specific DNA binding (GO:0043565), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): chromatin (GO:0000785), fibrillar center (GO:0001650), nucleus (GO:0005634), nuclear body (GO:0016604)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
identical protein binding	1
protein dimerization activity	1
DNA binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
chromosome	1
nucleolus	1
intracellular membrane-bounded organelle	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

670 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF174	GPKOW	Q92917	727
ZNF174	MZF1	P28698	463
ZNF174	ZSCAN1	Q8NBB4	463
ZNF174	ZNF202	O95125	440
ZNF174	MEFV	O15553	425
ZNF174	ZSCAN2	Q7Z7L9	423
ZNF174	CSF1	P09603	390
ZNF174	PDGFB	P01127	387
ZNF174	D6RC18	D6RC18	355
ZNF174	ANGEL2	Q5VTE6	327
ZNF174	ISY1	Q9ULR0	322
ZNF174	IGF2	P01344	321
ZNF174	K7ESF6	K7ESF6	309
ZNF174	NBPF3	Q9H094	305
ZNF174	ZNF205	O95201	300

IntAct

28 interactions, top by confidence:

A	B	Type	Score
ZNF397	ZNF213	psi-mi:“MI:0914”(association)	0.640
ZNF174	ZSCAN32	psi-mi:“MI:0915”(physical association)	0.550
ZSCAN32	ZNF197	psi-mi:“MI:0914”(association)	0.530
ZNF483	ZNF197	psi-mi:“MI:0914”(association)	0.530
PGBD1	ZNF213	psi-mi:“MI:0914”(association)	0.530
ZKSCAN4	ZNF213	psi-mi:“MI:0914”(association)	0.530
ZNF18	ZMYM6	psi-mi:“MI:0914”(association)	0.530
ZNF396	ZNF24	psi-mi:“MI:0914”(association)	0.530
ZNF213	ZNF24	psi-mi:“MI:0914”(association)	0.530
TPD52	TPD52L2	psi-mi:“MI:0914”(association)	0.530
ZNF174	CDK6	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
ZNF174	ZNF174	psi-mi:“MI:0915”(physical association)	0.370
ZNF174	FAM171A2	psi-mi:“MI:0914”(association)	0.350
ZNF232	ZNF197	psi-mi:“MI:0914”(association)	0.350
ZSCAN1	ZNF213	psi-mi:“MI:0914”(association)	0.350
ZSCAN23	ZNF263	psi-mi:“MI:0914”(association)	0.350
ZSCAN21	IPO8	psi-mi:“MI:0914”(association)	0.350
ZNF174	EIF3J	psi-mi:“MI:0914”(association)	0.350
TGIF2	ZNF213	psi-mi:“MI:0914”(association)	0.350
H2BC10	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
CDC14B	PES1	psi-mi:“MI:2364”(proximity)	0.270
ZMYM2	ZBTB5	psi-mi:“MI:2364”(proximity)	0.270
ZMYM2	TRIM24	psi-mi:“MI:2364”(proximity)	0.270
ZMYM3	TAF4	psi-mi:“MI:2364”(proximity)	0.270
SUMO1	CHD2	psi-mi:“MI:0914”(association)	0.000

BioGRID (97): ZNF174 (Affinity Capture-RNA), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Proximity Label-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Two-hybrid), ZNF174 (Proximity Label-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS), ZNF174 (Affinity Capture-MS)

ESM2 similar proteins: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A6NDS4, A6NER0, A6QPT6, B9A6J9, M3WHG5, O14771, O15482, O15553, O19110, O76081, P0C7X1, P0C7X3, P0C7X4, P35125, P48778, P48967, P79209, Q13670, Q15697, Q2TBC4, Q3T191, Q3UZD7, Q4R2Z8, Q5DRQ5, Q5SSQ6, Q5XFX8, Q69ZB3, Q6DHY5, Q6IPX1, Q6ZMN8, Q8BLR5, Q8BWA8, Q8IYF1, Q8IZP1, Q8JZW5, Q8N7G0

Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

69 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

384 predictions. Top by Δscore:

Variant	Effect	Δscore
16:3402403:GTGG:G	donor_gain	1.0000
16:3402400:GCA:G	donor_gain	0.9900
16:3402402:AGTGG:A	donor_loss	0.9900
16:3402405:GGGT:G	donor_loss	0.9900
16:3402406:GGTAA:G	donor_loss	0.9900
16:3402407:G:GG	donor_gain	0.9900
16:3402408:T:A	donor_loss	0.9900
16:3404970:GC:G	donor_gain	0.9900
16:3404971:C:G	donor_gain	0.9900
16:3402404:TGG:T	donor_gain	0.9800
16:3402405:GG:G	donor_gain	0.9800
16:3402405:GGG:G	donor_gain	0.9800
16:3402406:GG:G	donor_gain	0.9800
16:3404965:C:G	donor_gain	0.9800
16:3402412:G:GT	donor_gain	0.9700
16:3402413:A:T	donor_gain	0.9700
16:3408320:GA:G	acceptor_gain	0.9600
16:3408319:A:AG	acceptor_gain	0.9500
16:3408320:G:GG	acceptor_gain	0.9500
16:3404423:TAG:T	acceptor_loss	0.9400
16:3404424:A:C	acceptor_loss	0.9400
16:3404425:G:GT	acceptor_loss	0.9400
16:3402402:A:AG	donor_gain	0.9200
16:3402409:AAG:A	donor_loss	0.9100
16:3402368:G:GT	donor_gain	0.9000
16:3402403:GTGGG:G	donor_gain	0.8900
16:3402404:TGGGT:T	donor_gain	0.8900
16:3402406:G:A	donor_gain	0.8900
16:3404644:GACAG:G	donor_loss	0.8900
16:3404645:ACAG:A	donor_loss	0.8900

AlphaMissense

2673 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:3408698:T:C	F335L	1.000
16:3408700:C:A	F335L	1.000
16:3408700:C:G	F335L	1.000
16:3408782:T:C	F363L	0.999
16:3408784:T:A	F363L	0.999
16:3408784:T:G	F363L	0.999
16:3408866:T:C	F391L	0.999
16:3408868:T:A	F391L	0.999
16:3408868:T:G	F391L	0.999
16:3408699:T:C	F335S	0.998
16:3408725:C:G	H344D	0.998
16:3408809:C:G	H372D	0.997
16:3408823:C:A	H376Q	0.997
16:3408823:C:G	H376Q	0.997
16:3408867:T:C	F391S	0.997
16:3408677:T:C	C328R	0.996
16:3408717:T:C	L341P	0.996
16:3408727:C:A	H344Q	0.996
16:3408727:C:G	H344Q	0.996
16:3408739:C:A	H348Q	0.996
16:3408739:C:G	H348Q	0.996
16:3408783:T:C	F363S	0.996
16:3408801:T:C	L369P	0.996
16:3408811:C:A	H372Q	0.996
16:3408811:C:G	H372Q	0.996
16:3408821:C:G	H376D	0.996
16:3408686:T:A	C331S	0.995
16:3408686:T:C	C331R	0.995
16:3408687:G:C	C331S	0.995
16:3408688:T:G	C331W	0.995

dbSNP variants (sampled 300 via entrez): RS1000169149 (16:3404517 C>T), RS1000540005 (16:3407024 C>A,T), RS1000541786 (16:3405548 A>G), RS1000553807 (16:3400130 A>G,T), RS1000688036 (16:3400359 C>A), RS1001494711 (16:3399634 T>C), RS1001775615 (16:3404621 G>A,C), RS1001848094 (16:3400903 C>T), RS1001988921 (16:3406199 G>C), RS1002121467 (16:3400981 G>A,C), RS1002508974 (16:3403712 C>T), RS1003424276 (16:3406193 T>C), RS1003492380 (16:3407309 T>G), RS1003522570 (16:3401581 C>T), RS1003974617 (16:3403220 A>AGTG)

Disease associations

OMIM: gene MIM:603900 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): long QT syndrome (MONDO:0002442)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	3
sodium arsenite	decreases expression, increases abundance	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
beta-lapachone	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Leflunomide	decreases expression	1
Arsenic	increases abundance, decreases expression	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Hydrogen Peroxide	increases expression	1
Manganese	decreases expression, increases abundance	1
Mercury	decreases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Zinc	decreases expression	1
Cyclosporine	decreases expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TZ35	HAP1 ZNF174 (-) 1	Cancer cell line	Male
CVCL_TZ36	HAP1 ZNF174 (-) 2	Cancer cell line	Male
CVCL_XW12	HEK293 eGFP-ZNF174	Transformed cell line	Female

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea